A first-in-human clinical trial of sirpiglenastat (DRP-104) is currently ongoing and will further explore this hypothesis in a LUAD cohort (NCT04471415).Sarah LeBoeufRay PillaiShih Ming HuangTriantafyllia KarakousiWarren WuVolkan Sayin
Through this trial, we will test the hypothesis that glutamine antagonism in FLC reverses resistance to immune checkpoint inhibitor (ICI) therapy through modulating the TiME.Methods:We are conducting a single-arm phase 1b/2 clinical trial of glutamine antagonist DRP-104 in combination with ...
This data provides additional rationale for the ongoing phase I/II clinical trial (NCT04471415) using DRP-104 in NSCLC with mutations in KEAP1 as well as for combining DRP-104 with checkpoint blockade.Ray PillaiSarah LeBoeufAli Rashidfarrokhi...